Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

312.33 +1.85 (+0.60%)
Streaming Delayed Price Updated: 1:54 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 Next >
BeOne Medicines to Present at Upcoming Investor Conferences
From BeOne Medicines Ltd.
Via Business Wire
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally 
Via The Motley Fool
Topics Regulatory Compliance
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
From BeOne Medicines Ltd.
Via Business Wire
Where BeOne Medicines Stands With Analysts
 
Via Benzinga
Analyst Expectations For BeOne Medicines's Future
 
Via Benzinga
What's Going On With Summit Therapeutics Stock On Monday?
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025. 
Via Benzinga
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
From BeOne Medicines Ltd.
Via Business Wire
A Glimpse of BeiGene's Earnings Potential
 
Via Benzinga
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
BeiGene's Earnings: A Preview
 
Via Benzinga
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress. 
Via Benzinga
Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From BeOne Medicines Ltd.
Via Business Wire
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
From BeOne Medicines Ltd.
Via Business Wire
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
From BeOne Medicines Ltd.
Via Business Wire
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
Earnings Scheduled For August 8, 2025
 
Via Benzinga
BeOne Medicines (ONC) Q2 EPS Soars 924%
Via The Motley Fool
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
From BeOne Medicines Ltd.
Via Business Wire
Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.